Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes.
Beattie R, Furrer K, Dolan DP, Curioni-Fontecedro A, Lee DN, Frauenfelder T, Hoeller S, Weder W, Bueno R, Opitz I, Swanson S. Beattie R, et al. Among authors: furrer k. Eur J Cardiothorac Surg. 2021 Dec 1;60(6):1297-1305. doi: 10.1093/ejcts/ezab340. Eur J Cardiothorac Surg. 2021. PMID: 34331065
Extended resection for potentially operable patients with stage III non-small cell lung cancer after induction treatment.
Furrer K, Weder W, Eboulet EI, Betticher D, Pless M, Stupp R, Krueger T, Perentes JY, Schmid RA, Lardinois D, Furrer M, Früh M, Peters S, Curioni-Fontecedro A, Stahel RA, Rothschild SI, Hayoz S, Opitz I. Furrer K, et al. J Thorac Cardiovasc Surg. 2022 Dec;164(6):1587-1602.e5. doi: 10.1016/j.jtcvs.2022.03.034. Epub 2022 Apr 18. J Thorac Cardiovasc Surg. 2022. PMID: 35688713
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. König D, et al. Among authors: furrer k. ESMO Open. 2022 Apr;7(2):100455. doi: 10.1016/j.esmoop.2022.100455. Epub 2022 Apr 7. ESMO Open. 2022. PMID: 35398718 Free PMC article.
Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455].
König D, Schär S, Vuong D, Guckenberger M, Furrer K, Opitz I, Weder W, Rothschild SI, Ochsenbein A, Zippelius A, Addeo A, Mark M, Eboulet EI, Hayoz S, Thierstein S, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Pless M, Früh M. König D, et al. Among authors: furrer k. ESMO Open. 2022 Jun;7(3):100494. doi: 10.1016/j.esmoop.2022.100494. Epub 2022 Apr 22. ESMO Open. 2022. PMID: 35468561 Free PMC article. No abstract available.
27 results